Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells
News Mar 28, 2013
Various data, already presented at academic meetings, indicates that Medicyte’s upcyte® hepatocytes combine the benefits of quantity (generation of up to 2000 vials per donor) with the quality of primary hepatocytes. The new generation of upcyte® hepatocytes show more comparable results to primary cells in in-vitro assays (such as CYP 3A4-Induction, genotoxicity or hepato- and cytotoxicity). ‘With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market’ commented Dr. Joris Braspenning, CEO of Medicyte GmbH.
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE